These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21085470)

  • 21. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis.
    Paul J; Karmakar S; De T
    Eur J Immunol; 2012 Aug; 42(8):2087-99. PubMed ID: 22622993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptome Analysis Identifies Immune Markers Related to Visceral Leishmaniasis Establishment in the Experimental Model of BALB/c Mice.
    Agallou M; Athanasiou E; Kammona O; Tastsoglou S; Hatzigeorgiou AG; Kiparissides C; Karagouni E
    Front Immunol; 2019; 10():2749. PubMed ID: 31849951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
    Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
    Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F1 Domain of the
    Carrillo E; Fernandez L; Ibarra-Meneses AV; Santos MLB; Nico D; de Luca PM; Correa CB; de Almeida RP; Moreno J; Palatnik-de-Sousa CB
    Front Immunol; 2017; 8():750. PubMed ID: 28747911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leishmania donovani phosphoproteins pp41 and pp29 re-establishes host protective immune response in visceral leishmaniasis.
    Das P; Amit A; Singh SK; Chaudhary R; Dikhit MR; Yadav A; Pandey K; Das VN; Sundram S; Das P; Bimal S
    Parasitol Int; 2015 Feb; 64(1):18-25. PubMed ID: 25224164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
    Lehmann J; Enssle KH; Lehmann I; Emmendörfer A; Lohmann-Matthes ML
    J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
    Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.
    Mazumder S; Maji M; Das A; Ali N
    PLoS One; 2011 Feb; 6(2):e14644. PubMed ID: 21311597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
    Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
    Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live Attenuated
    Banerjee A; Bhattacharya P; Dagur PK; Karmakar S; Ismail N; Joshi AB; Akue AD; KuKuruga M; McCoy JP; Dey R; Nakhasi HL
    J Immunol; 2018 Jan; 200(1):163-176. PubMed ID: 29187586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.
    Kedzierska K; Curtis JM; Valkenburg SA; Hatton LA; Kiu H; Doherty PC; Kedzierski L
    PLoS One; 2012; 7(3):e33161. PubMed ID: 22470440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
    Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF
    Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.
    Sabur A; Bhowmick S; Chhajer R; Ejazi SA; Didwania N; Asad M; Bhattacharyya A; Sinha U; Ali N
    Front Immunol; 2018; 9():18. PubMed ID: 29441060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.
    Wang Q; Barry MA; Seid CA; Hudspeth EM; McAtee CP; Heffernan MJ
    J Biomed Mater Res B Appl Biomater; 2018 May; 106(4):1587-1594. PubMed ID: 28804955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.